<DOC>
	<DOCNO>NCT01908192</DOCNO>
	<brief_summary>The purpose study determine NaBen® safe effective add-on treatment schizophrenia adolescent .</brief_summary>
	<brief_title>Adaptive Phase II Study Evaluate Safety &amp; Efficacy NaBen®</brief_title>
	<detailed_description>This two-part , multi-center , prospective , randomize , placebo-controlled , parallel-group study , adolescent subject schizophrenia enrol . Overall , eligible subject randomize pre-defined 1:1 ratio NaBen® placebo . This study conduct two part : In Part 1 ( Phase IIb ) study , 76 subject ( ~ 60 % total planned subject ) randomize 1:1 ratio ( NaBen® placebo ) , 38 subject randomize NaBen® group 38 subject placebo group . An interim analysis ( IA ) conduct randomization 76th subject Part 1 study . The data analyze enrolled subject Part 1 study complete Visit 5 ( week 6 ) withdrawn study , whichever occur first . The data IA review independent Data Safety Monitoring Committee ( DSMC ) responsible review data Part 1 ( Phase IIb ) study safety effectiveness . In Part 2 ( Phase III ) study , total 50 subject randomize , 25 subject randomize NaBen® group 25 subject placebo group . The final subject number study depend sample size re-estimation Part 1 study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Male female subject 12 17 year age inclusive Physician confirm DSMIV V diagnosis schizophrenia base MINI International Neuropsychiatric Interview Schizophrenia Psychotic Disorders Studies Children Adolescents , version 6.0 ( MINIKID , Version 6.0 ) Are clinically stable residual symptom , define total score ≥ 60 PANSS score ≥ 40 SANS An unchanged antipsychotic medication regimen least eight ( 8 ) week prior randomization study expect remain unchanged study ( longer depot longacting antipsychotic : ten ( 10 ) month Aripiprazole ( Maintena® ) Paliperidone ( Xeplion® ) ; six ( 6 ) month Olanzapine pamoate monohydrate ( Zypadhera® ) ; least 6 time duration report half life minimum four ( 4 ) month depot longacting antipsychotic ) In good general physical health physical exam , neurological exam laboratory assessment ( urine/blood routine , biochemical test ECG ) clinically unremarkable per investigator Subject negative urine illicit drug screen test Subject understand willing sign Informed Assent Form ( IAF ) prior study entry agree available study visit The subject 's guardian understands willing sign Informed Consent Form ( ICF ) prior study entry agree available study visit Must danger self others must family support available maintain outpatient Meets DSMIV V criterion screen mental retardation , dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substance induce psychotic disorder . Other comorbid disorder ; e.g. , attentiondeficit hyperactivity disorder ( ADHD ) , allow long schizophrenia primary diagnosis comorbid disorder ( ) require medication . Subjects whose illness resistant antipsychotic accord prior trial two different antipsychotic adequate dose History epilepsy , head trauma , neurological illness Tourette 's syndrome History allergic reaction sodium benzoate Serious medical illness acute chronic renal disease , liver failure heart disease , opinion investigator , may interfere conduct study . Current substance abuse positive urine illicit drug screen history substance dependence ( include alcohol , exclude nicotine caffeine ) past three ( 3 ) month . Use depot antipsychotic past six ( 6 ) month Inability follow protocol Body Mass Index ( BMI ) &gt; 35 Female subject pregnant ( confirmed urine pregnancy test perform screen Visit ) nursing , agree abstinence birth control study Cancer within last three ( 3 ) year except basal cell carcinoma squamous cell carcinoma Previous participation intervention trial within 30 day randomization Subjects whose PANSS score decrease 10 percent Screening Phase</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sodium Benzoate</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Anti-psychotic</keyword>
	<keyword>NMDA</keyword>
	<keyword>NaBen</keyword>
	<keyword>pediatric</keyword>
</DOC>